Spots Global Cancer Trial Database for metastatic neuroendocrine tumor
Every month we try and update this database with for metastatic neuroendocrine tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | NCT00137774 | Neuroendocrine ... | Bevacizumab Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | NCT04234568 | Metastatic Dige... Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | NCT01841736 | Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest... | Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | NCT00137774 | Neuroendocrine ... | Bevacizumab Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | NCT05724108 | Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | NCT05724108 | Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | NCT00165230 | Neuroendocrine ... | Thalidomide Temodar | 18 Years - | Dana-Farber Cancer Institute | |
| Phase 2 Study of ONC201 in Neuroendocrine Tumors | NCT03034200 | Recurrent Neuro... Metastatic Neur... | ONC201 | 14 Years - | Case Comprehensive Cancer Center | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | NCT01841736 | Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest... | Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
